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A SLOWLY PROGRESSIVE MITOCHONDRIAL
ENCEPHALOMYOPATHY WIDENS THE
SPECTRUM OF AIFM1 DISORDERS
To date, 3 AIFM1 (apoptosis inducing factor mitochon-
drial 1, located on Xq26.1) mutations have been re-
ported: 2 missense changes (c.923G.A/p.Gly308Glu;
c.1478A.T/p.Glu493Val) and a 3-basepair deletion
(c.601delAGA/p.Arg201del). Two mutations have
been described in early-onset severe mitochondrial
encephalomyopathy related to impaired oxidative
phosphorylation.1,2 A third mutation is associated
with Cowchock syndrome, or Charcot-Marie-Tooth
X4 (CMTX4), a slowly progressive disorder charac-
terized by axonal neuropathy, hearing loss, and
mental retardation.3,4
Case history. We report a 39-year-old man with an
early-onset, slowly progressive mitochondrial disease
associated with a novel AIFM1 mutation, thus
widening the clinical spectrum of AIFM1-related
disorders.
The patient’s family history was unremarkable.
Psychomotor development was normal until age
1 year, when he started to show walking difficulties.
During childhood, he developed gait and limb ataxia
(sensory and cerebellar), hearing loss, and cognitive
impairment. Visual deficit and distal muscle wasting
and weakness became evident at puberty, with
scanned speech, head and trunk titubation, and
intention tremor, progressively more marked at
repeated neurologic examinations. He became chair-
bound at age 20 years, needed acoustic aids at age 22
years, and developed progressive sleep apnea syn-
drome since age 23 years. At age 30 years, visual loss
had progressed to 1-2/10 bilaterally. Only one (13
years) of several assays showed elevated lactate and
pyruvate serum levels (3,051 mmol/L, normal value
580–2,100; 146 mmol/L, normal value 40–140
mmol/L, respectively). Brain CT scan and MRI were
normal at age 9 years, subsequently showing cerebel-
lar atrophy (19 years) and mild cortical and thalamic
atrophy (30 years). At last MRI (35 years), further
involvement of bulbar olives, dentate nuclei,
and spinal cord (slight cervical atrophy with T2
hyperintensity in posterior columns) were observed
( F1figure, A–C). Brain spectroscopy was normal. Nerve
conduction study showed a moderate-to-severe axo-
nal, more sensory than motor, neuropathy. EEG was
normal. Optic atrophy and retinopathy were docu-
mented by visual evoked potentials (since his teens)
and electroretinogram (25 years).
Results. Informed consent was obtained for biochem-
ical and genetic analyses. Muscle biopsy (13 years)
showed evidence of chronic denervation, ragged-red
fibers, and fibers hyporeactive to cytochrome c oxidase
(complex IV [cIV]) histochemical staining. Biochemical
analysis revealed markedly reduced cIV activity, with
partial reduction of other mitochondrial electron
transfer chain (ETC) complex activities and increase
of citrate synthase (figure, D). Mitochondrial DNA
Southern blot and screening for POLG1, SURF1,
SCO1, and COX15 mutations were normal.
Coenzyme Q10 and riboflavin supplementation did
not modify clinical course. Recently, sequencing of a
panel containing more than 100 nuclear genes
associated with mitochondriopathies revealed a
hemizygous c.784G.A/p.Gly262Ser mutation in
AIFM1 (NM_004208) (figure, E), the gene encoding
apoptosis-inducing factor (AIF). This variant, inherited
from the healthy mother (figure, F), is not reported in
public databases, is predicted as probably pathogenic
(table e-1 on the Neurology® Web site at Neurology.
org), and affects a conserved amino acid residue (table
e-2).Western blot analysis on patient fibroblasts showed
strong reduction in AIF amount (figure, G), indicating
instability of the mutant protein and confirming a
deleterious outcome of the identified variant.
Discussion. AIF is a mitochondrial flavoprotein,
attached by an N-terminal transmembrane domain
to the inner mitochondrial membrane, with a poorly
defined (FAD-dependent) NADH oxidase activity
and a role in caspase-independent cell death.5 AIF
defects can result in loss of its pro-survival function
related to assembly/stabilization of ETC, or in
increased pro-death activity, facilitating AIF
translocation from mitochondria to the nucleus and
eventually leading to DNA fragmentation.6 The few
cases with AIFM1 mutations previously reported are
summarized in table e-3. Patients with a severe
outcome included 2 cousins with early-onset, severe
psychomotor delay, extrapyramidal signs, epilepsy,
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and axonal sensory-motor neuropathy associated with
bilateral striatal necrosis1; and 2 siblings with prenatal
ventriculomegaly.2 Recently, AIFM1 mutation was
found in a family with CMTX4.3,4 Mitochondrial
encephalomyopathy with moderate clinical severity,
slow progressive course despite early onset, and
cerebellar involvement was not reported until now.
Notwithstanding common clinical and instrumental
features, the cases reported to date are heterogeneous.
Even the biochemical profile is inconsistent, with
multiple ETC deficiency reported in muscle for the
most severe cases, mainly cIV deficiency found in the
present patient, and normal activities described in
CMTX4 individuals. These observations are partly
in contrast with data obtained from mouse models
suggesting that knockdown or knockout of AIF led to
complex I deficiency, particularly in brain.7However,
biochemical defects seem to reflect the clinical
severity in patients, confirming the importance of
AIF for proper ETC functioning and indicating
that this AIF role is fundamental to reduce neuronal
damage. Moreover, this case confirms the usefulness
of broad genetic screening, for instance targeted
sequencing, in highly heterogeneous syndromes
resembling mitochondrial disorders.
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Figure Brain MRI, biochemical, and genetic features
(A) Sagittal T2-weighted image. (B) Coronal fluid-attenuated inversion recovery image. (C) Axial proton density–weighted image. (A–C) Diffuse cerebellar
atrophy. Hyperintensity of dentate (B, arrow on the right) and olivar (C, arrow on the right) nuclei are also present. (D) Activities of mitochondrial respiratory
chain complexes (cI, cI 1 III, cII, cII 1 III, cIV) in patient muscle homogenate, reported as percentages of the controls mean. The specific activities were
normalized for citrate synthase (CS) activity. (E) Snapshot from IGV software of the region containing the mutation identified in the patient. AIFM1 is on the
reverse strand, hence the highlighted nucleotide (T) corresponds to the complementary of mutant c.784A. (F) Family pedigree shows the segregation of the
c.784G.A mutation. The mother, heterozygous for the mutation, was asymptomatic; none of her 6 siblings has ever presented signs of mitochondrial
disorder. No neurophysiologic testing was performed. (G) Western blot analysis of fibroblasts from patient (Pt) and controls (Ct1, Ct2, Ct3) using antibodies
against AIFM1 and GAPDH, the latter used as loading control. The reported percentages correspond to the values of AIFM1/GAPDH signals obtained by
densitometric analysis. One hundred percent corresponds to the mean value from controls.
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